CHICAGO — On this video, Shahzad Raza, MD, discusses teclistamab as a possible remedy for sufferers with relapsed or refractory systemic gentle chain amyloidosis.
“Teclistamab has already been accredited in a number of myeloma, and there may be institutional information the place it exhibits that it’s additionally protected and efficient,” Raza, a hematologist-oncologist at Cleveland Clinic Taussig Most cancers Institute, stated. “This class is definitely coming in gentle chain amyloidosis, which is sort of promising, and I actually see hope for these sufferers sooner or later.”
Reference:
Mico V, et al. Summary 7562. Offered at: ASCO Annual Assembly; Could 30-June 3, 2025; Chicago.
Revealed by:
